Proper usage of pancreatic enzymes.
With the recognition of the close link between nutritional status and pulmonary function in cystic fibrosis (CF), treatment and prevention of malnutrition have become a major focus in the modern therapeutic approach for patients with CF. Thereby, pancreatic enzyme replacement therapy plays a central role. This article reviews key publications on important aspects of pancreatic enzyme replacement therapy contained in the literature over the last 12 months. New insights into the pathogenesis of exocrine pancreatic disease, efficacy and dosing of pancreatic enzyme preparations, occurrence of fibrosing colonopathy, enzyme replacement in the context of enteral nutrition, and assessment of pancreatic function are addressed.
Schibli
Susanne
S
The Hospital for Sick Children, Division of Gastroenterology and Nutrition, Toronto, ON, Canada. susanne.schibli@sickkids.ca
Durie
Peter R
PR
Tullis
Elizabeth D
ED
D003108:Colonic Diseases / Q000139:chemically induced; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000503:physiopathology; D004334:Drug Administration Schedule; D006801:Humans; D010194:Pancreatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D016896:Treatment Outcome
D010194:Pancreatin